BioSpace News Archive

The deal adds LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations, to its pipeline.

Many factors contribute to community-building COVID herd immunity. Are we close to having herd immunity against Covid-19? Can we achieve that? Let’s find the answer.

Starting your new pharmacy job can be scary, especially if you have never worked in a pharmacy before. Here is what to expect on your first day.

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the company will host a live investor and analyst webcast on Tuesday, November 30, 2021 reporting on data from the ongoing global Phase 2 TIDAL study evaluating zandelisib in patients with relapsed or refractory follicular lymphoma.

Outlook Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 46,000,000 shares of common stock of the Company at a price to the public of $1.25 per share, which includes the exercise in full of the underwriter’s option to purchase additional shares.

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of D360 version 21.5, an industry-leading scientific informatics software for discovery scientists to integrate many data sources and analyze small molecules and biologic drugs for fast, high-confidence go/no-go decisions.

CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, reminded investors that Dr. Scott Kelly, CytoDyn’s Chairman of the Board, Chief Medical Officer and Head of Business Development, will present at the World Antiviral Congress being held tomorrow, November 30, 2021 through Thursday, December 2, 2021.

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the 4th Annual Evercore ISI HealthCONx Conference.

Vector Space Biosciences, parent company of Vectorspace AI, announces the following three additions to its Scientific Advisory Board (SAB).

Pasithea Therapeutics Corp., a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, announced the closing of its previously announced private placement of common stock and warrants priced at a premium to the market under Nasdaq rules.